Carbapenem-Resistant Enterobacterales
A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Mechanism and Evolution of Antibiotic Resistance".
Deadline for manuscript submissions: closed (15 September 2022) | Viewed by 7035
Special Issue Editors
Interests: antibiotic resistance; Klebsiella pneumoniae; Escherichia coli; Pseudomonas aeruginosa; epidemiology surveillance studies; novel β-lactam-β-lactamase inhibitor combinations; whole genome sequencing
Special Issue Information
Dear Colleagues,
Carbapenem-resistant Enterobacterales isolates have become an increasing threat to public health worldwide due to the limited therapeutic options for their treatment and the high rate of associated morbidity and mortality. Carbapenem resistance is usually mediated by the production of transferable carbapenemase enzymes, frequently combined with other resistance mechanisms, such as efflux pumps, enzymatic degradation, porin mutations, and target–site alterations. Carbapenemase enzymes are classified into different molecular classes: class A (e.g., KPC and GES), class B (or metallo-β-lactamases (MBLs)) (e.g., VIM, IMP and NDM), and class D (or oxacillinases (OXA-type)). Carbapenemases are often contained on mobile genetic platforms, such as plasmids and transposons, that frequently harbor resistance determinants to other antibiotic groups, contributing to the emergence of multidrug-resistant pathogens. Carbapenemase production is normally linked to successful multidrug-resistant clones, particularly K. pneumoniae high-risk clones, commonly associated with healthcare related infections and with a high capacity of persistence in hospital settings.
Therefore, the main subject of this Special Issue includes any approach to characterizing the epidemiology, antibiotic susceptibility profiles, and resistance mechanisms involved in carbapenem resistant Enterobacterales isolates, as well as any study focused on improving the implementation of infection control measures targeted towards reducing the prevalence of these multidrug-resistant Gram-negative bacteria and to develo** safe alternative treatment options.
Dr. Marta Hernández-García
Dr. Rosa Del Campo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at mdpi.longhoe.net by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Carbapenemase-producing Enterobacterales
- Plasmids
- Co-resistance
- Nosocomial infections
- K. pneumoniae high-risk clones
- Infection control measures